CLINICAL RESEARCH: POLYMORPHISMS AND CORONARY DISEASE
Genetic Polymorphism on Endothelial Nitric Oxide Synthase Affects Endothelial Activation and Inflammatory Response During the Acute Phase of Myocardial Infarction
Charalambos Antoniades, MD,
Dimitris Tousoulis, MD, PhD, FACC*,
Carmen Vasiliadou, BSc, MSc,
Christos Pitsavos, MD, FACC, FESC,
Christina Chrysochoou, MD,
Demosthenis Panagiotakos, BSc, MSc, PhD,
Costas Tentolouris, MD, FACC, FESC,
Kyriakoula Marinou, MD,
Nikolaos Koumallos, MD and
Christodoulos Stefanadis, MD, PhD, FACC, FESC
Cardiology Department, Athens University Medical School, Hippokration Hospital, Athens, Greece
Manuscript received April 1, 2005;
revised manuscript received May 16, 2005,
accepted May 22, 2005.
* Reprint requests and correspondence: Dr. Dimitris Tousoulis, Athens University Medical School, S Karagiorga 69, Glifada, Athens, Greece (Email: tousouli{at}med.uoa.gr).
Genetic Polymorphism on Endothelial Nitric Oxide Synthase Affects Endothelial Activation and Inflammatory Response During the Acute Phase of Myocardial Infarction
Charalambos Antoniades, Dimitris Tousoulis, Carmen Vasiliadou, Christos Pitsavos, Christina Chrysochoou, Demosthenis Panagiotakos, Costas Tentolouris, Kyriakoula Marinou, Nikolaos Koumallos, Christodoulos Stefanadis
We evaluated the effect of G894T polymorphism on endothelial nitric oxide synthase gene on the risk for premature myocardial infarction (MI) and on the release of von Willebrand factor (vWF), interleukin (IL)-6, IL-1b, and oxidized low-density lipoprotein (ox-LDL) levels during the acute phase of premature MI and one year after the event. We found that G894T polymorphism on the endothelial nitric oxide synthase gene increases the risk for premature MI and modifies the response of vascular endothelium during the acute phase of MI by affecting the release of vWF, IL-6, and oxidative stress status, an effect diminished one year after the event.
OBJECTIVES: This study sought to evaluate the effect of genetic polymorphism G894T on endothelial nitric oxide synthase (eNOS); on the risk for myocardial infarction (MI); and on the release of von Willebrand factor (vWF), interleukin (IL)-6, IL-1b, and oxidized low-density lipoprotein (ox-LDL) levels during the acute phase of MI and one year after the event.
BACKGROUND: Genetic polymorphism G894T on eNOS has been associated with increased cardiovascular risk. However, its role during the acute phase of MI is unknown.
METHODS: The study population consisted of 228 patients with a first event of premature MI and 519 matched control patients. One year after the event, 61 patients and 205 control patients were recalled for the follow-up study. Blood sampling was performed during the acute phase and after one year.
RESULTS: The risk for MI in 894TT was 1.992 (95% confidence interval [CI], 1.131 to 3.485), p < 0.05 versus GG+GT; 2.038 (95% CI, 1.125 to 3.695), p < 0.05 versus GG; and 2.009 (95% CI, 1.106 to 3.651), p < 0.05 versus GT. During the acute phase, vWF was higher in GT+TT (121.02 ± 5.47%) versus GG (84.6 ± 7.1%, p < 0.01), an effect persisting after one year (90.4 ± 3.8 vs. 73.1 ± 4.6%, p < 0.01). During the acute phase, GT+TT had higher ox-LDL and IL-6 (131.2 ± 6.4 IU/l and 8.5 ± 0.7 pg/ml) compared with GG (101.7 ± 9.64 IU/l and 6.2 ± 0.8 pg/ml, p < 0.05 for both), but no difference was found at one year.
CONCLUSIONS: G894T polymorphism on the eNOS gene increases the risk for premature MI and modifies the response of vascular endothelium during the acute phase of MI by affecting the release of vWF, IL-6, and oxidative stress status, an effect diminished one year after the event.
|
Abbreviations and Acronyms
| | CABG = coronary artery bypass grafting | | eNOS = endothelial nitric oxide synthase | | HDL = high-density lipoprotein | | IL = interleukin | | MI = myocardial infarction | | NO = nitric oxide | | ox-LDL = oxidized low-density lipoprotein | | PCI = percutaneous coronary intervention | | vWF = von Willebrand factor |
|
This article has been cited by other articles:
|
|
|
|
 
E. Galluccio, P. Piatti, L. Citterio, P. C. G. Lucotti, E. Setola, L. Cassina, M. Oldani, I. Zavaroni, E. Bosi, A. Colombo, et al.
Hyperinsulinemia and impaired leptin-adiponectin ratio associate with endothelial nitric oxide synthase polymorphisms in subjects with in-stent restenosis
Am J Physiol Endocrinol Metab,
May 1, 2008;
294(5):
E978 - E986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Imamura, R. Takahashi, R. Murakami, H. Kataoka, X. W. Cheng, Y. Numaguchi, T. Murohara, and K. Okumura
The effects of endothelial nitric oxide synthase gene polymorphisms on endothelial function and metabolic risk factors in healthy subjects: the significance of plasma adiponectin levels
Eur. J. Endocrinol.,
February 1, 2008;
158(2):
189 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Antoniades, D. Tousoulis, and C. Stefanadis
Effects of Endothelial Nitric Oxide Synthase Gene Polymorphisms on Oxidative Stress, Inflammatory Status, and Coronary Atherosclerosis: An Example of a Transient Phenotype
J. Am. Coll. Cardiol.,
March 20, 2007;
49(11):
1226 - 1226.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Rossi and M. Cesari
Reply
J. Am. Coll. Cardiol.,
March 20, 2007;
49(11):
1226 - 1227.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. T. Morozowich, B. S. Donahue, and I. J. Welsby
Genetics of coagulation: considerations for cardiac surgery.
Seminars in Cardiothoracic and Vascular Anesthesia,
December 1, 2006;
10(4):
297 - 313.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. P. Casas, G. L. Cavalleri, L. E. Bautista, L. Smeeth, S. E. Humphries, and A. D. Hingorani
Endothelial Nitric Oxide Synthase Gene Polymorphisms and Cardiovascular Disease: A HuGE Review
Am. J. Epidemiol.,
November 15, 2006;
164(10):
921 - 935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Zhang, R. Lopez-Ridaura, D. J. Hunter, N. Rifai, and F. B. Hu
Common variants of the endothelial nitric oxide synthase gene and the risk of coronary heart disease among u.s. Diabetic men.
Diabetes,
July 1, 2006;
55(7):
2140 - 2147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
